COMMUNIQUÉS West-GlobeNewswire

Bone Therapeutics to participate in upcoming conferences
31/05/2019
Press Release Gosselies, Belgium, 31 May 2019, 7 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the leading biotech company focused on the development of innovative cell and biological therapeutics to [...]
Bone Therapeutics annonce sa participation à plusieurs évènements sectoriels
31/05/2019
Communiqué de presse Gosselies, Belgique, le 31 Mai 2019, 7h00 CEST – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins médicaux non [...]
Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care
31/05/2019
Roche and GE Healthcare launch NAVIFY Tumor Board with medical imaging capabilities to enable more personalised treatment decisions in cancer care Radiologists can now upload their patient records to the same dashboard [...]
Myovant Sciences Announces Pricing of $125 Million Public Offering of Common Shares
31/05/2019
BRISBANE, Calif. and BASEL, Switzerland, May 30, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) (“ Myovant ”), a clinical-stage healthcare company focused on developing and commercializing innovative therapies [...]
Amicus Therapeutics Prices Underwritten Offering of Common Stock
31/05/2019
CRANBURY, N.J., May 30, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the pricing of an underwritten offering of 16,279,070 shares of its common stock at $10.75 per share. The gross [...]
Ascent Industries Provides Bi-Weekly Default Status Report
31/05/2019
VANCOUVER, British Columbia, May 30, 2019 (GLOBE NEWSWIRE) -- Ascent Industries Corp. ( CSE: ASNT ) (“ Ascent ” or the “ Company ”) is providing this bi-weekly default status report in accordance with National Policy 12 [...]
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended March 31, 2019
31/05/2019
Major corporate milestone achieved in initiating BLA filing with FDA for Mesoblast’s cell therapy in the treatment of acute graft versus host disease MELBOURNE, Australia and NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- [...]
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
31/05/2019
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer
31/05/2019
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Extendicare Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders and Board Changes
31/05/2019
MARKHAM, Ontario, May 30, 2019 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced the results of matters voted on at its annual and special shareholders’ meeting held on May [...]
Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2019
31/05/2019
TORONTO, May 30, 2019 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE: 31R) ("Revive" or the “Company”) , a specialty cannabis company focused on the research, development and [...]
Helix BioPharma Corp. Initiates OTCQB Application and Hires U.S. Investor Relations Firm
30/05/2019
RICHMOND HILL, Ontario, May 30, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of [...]
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
30/05/2019
SOUTH SAN FRANCISCO, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with [...]
Aurora Spine Corporation Reports Record Q1 Revenue; Files Condensed Interim Consolidated Financial Statements For the Three Months Ended March 31, 2019
30/05/2019
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif., May 30, 2019 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) announces financial [...]
Cambium Networks Files Registration Statement with SEC for an Initial Public Offering
30/05/2019
ROLLING MEADOWS, Ill., May 30, 2019 (GLOBE NEWSWIRE) -- Cambium Networks Corporation (“Cambium”), a provider of wireless broadband networking infrastructure solutions, today announced that it has filed a registration [...]
U.S. FDA Grants Priority Review for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
30/05/2019
Company Announcement U.S. FDA grants Priority Review for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients with multiple myeloma who are candidates for [...]
Dentsply Sirona to Present at the 2019 William Blair Growth Stock Conference on June 6th
30/05/2019
CHARLOTTE, N.C., May 30, 2019 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the Dental Solutions Company, today announced that it will participate in the 2019 William Blair Growth Stock [...]
XBiotech Announces Public Offering of Common Shares
30/05/2019
AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that it has commenced an underwritten public offering of common shares, subject to market and other conditions. XBiotech [...]
Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds
30/05/2019
DEVON, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]

Pages